CAI vs INCY
Caris Life Sciences, Inc. vs Incyte — AI-powered side-by-side comparison
CAI
Caris Life Sciences, Inc.
57
Watch
VS
| Metric | CAI | INCY |
|---|
| AI Score |
57
|
72
|
| Price |
$23.12
|
$121.08
|
| P/E Ratio |
62.22×
|
14.89×
|
| ROE |
-93.2%
|
24.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
69.7%
|
92.6%
|
| Debt / Equity |
0.76×
|
0.01×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
86.2
|
56.2
|
| Beta |
0.678
|
0.769
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for CAI versus INCY.
INCY leads by 15 points.
INCY scores 72/100 (Buy) versus CAI at 57/100 (Watch).
CAI Committee View
50% agreement
4 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 63.0% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- RSI at 86 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
- Bollinger bandwidth of 63.0% signals elevated volatility — Risk
INCY Committee View
100% agreement
6 analysts
The primary driver is revenue growing 26.9% yoy -- genuine top-line momentum. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 29.6% shows genuine earnings power backing the valuation — Value
- Revenue growing 26.9% YoY -- genuine top-line momentum — Growth
- EPS growing 80.3% YoY — Growth
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical